Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 4/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALPI | P09923 | 3/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829807 | 0.79 | ALPL (0.43) | PTGS2ALPLALPILRRK2PTGS1 | |
| SCHEMBL11126762 | 0.73 | AHR (0.44) | HSD17B3 | |
| SCHEMBL6830135 | 0.72 | PTGS2 (0.55) | PTGS2ALPLALPIPTGS1ALDH1A1 | |
| SCHEMBL6830161 | 0.71 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL23693718 | 0.68 | TSHR (0.56) | PTGS2MAPK1NPC1RAB9AKDM4E | |
| SCHEMBL29887043 | 0.68 | TSHR (0.56) | PTGS2MAPK1NPC1RAB9AKDM4E | |
| SCHEMBL29887138 | 0.68 | TSHR (0.56) | PTGS2MAPK1NPC1RAB9AKDM4E | |
| SCHEMBL11130218 | 0.67 | NQO1 (0.50) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL23693757 | 0.67 | TTR (0.51) | PTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL29886870 | 0.67 | TTR (0.51) | PTGS2PTGS1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347963-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| EP-1347963-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-6433005-B1 | SELECTIVE COX II INHIBITOR | SYNTEX (U.S.A.) LLC | 2002-08-13 | — | — | US | disclosed |
| US-20020107280-A1 | NEW BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | SYNTEX (U.S.A.) LLC | 2002-08-08 | — | — | US | disclosed |
| WO-2002046178-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107280-A1 | NEW BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | SULT1E1, SULT2A1, SULT1A1 | PTGS2 6/4885ENPP2 2456/4885HSD17B3 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.